Metformin Alleviated EMT and Fibrosis after Renal Ischemia-Reperfusion Injury in Rats

Min Wang,Xiaodong Weng,Jia Guo,Zhiyuan Chen,Guanjun Jiang,Xiuheng Liu
DOI: https://doi.org/10.3109/0886022x.2016.1149770
IF: 3.222
2016-01-01
Renal Failure
Abstract:Purpose The purpose of this study is to assess the potential effects of metformin on the development of EMT and tubulointerstitial fibrosis 12 weeks after acute renal ischemia-reperfusion. Methods Male Sprague-Dawley rats were randomly assigned to four groups: Sham, IRI, transient administration of metformin (TAM), and continuous administration of metformin (CAM). Metformin was administered i.p. at a dose of 125 mu g kg (- 1) d( - 1) 3 d prior to suffering from IRI (TAM), or from 3 d before suffering from IRI to 12 weeks after reperfusion (CAM). Renal function, histology, and expressions of IL-6, TNF-alpha, alpha-SMA, TGF-beta 1, Vimentin, and E-cadherin were analyzed. Results Tubulointerstitial fibrosis worsened further in IRI, accompanied by the increased expressions of interleukin-6, TNF-alpha, alpha-SMA, TGF-beta 1, Vimentin, and loss of E-cadherin. Although there were no significant differences between IRI and TAM (p > 0.05). Compared with the IRI, expressions of IL-6, TNF-alpha, alpha-SMA, TGF-beta 1, and Vimentin were reduced and the expression of E-cadherin was restored in CAM (p < 0.05). CAM also significantly promoted activation of AMPK (p < 0.05), which showed no difference among Sham, IRI, and TAM (p > 0.05). Conclusions CAM significantly attenuated tubulointerstitial fibrosis and EMT in rats, potentially via activation of AMPK and down-regulation of TGF-beta 1.
What problem does this paper attempt to address?